uMed Collect
The right patients, recruited faster.
uMed Recruit accelerates trial enrolment by delivering highly qualified, site-ready patient referrals through clinically validated EHR identification, multi-channel outreach, and a rigorous three-stage screening process.
Deep, longitudinal insight
Millions of accessible patients
High quality referrals
Rapid recruitment
The problem
The Recruitment Challenge
Sponsors, sites and patients each face barriers that slow or stall enrollment.
uMed Recruit solves these bottlenecks by identifying the right patients and engaging them quickly, consistently, and at scale.
EHR Screening
We identify eligible patients using clinically validated EMR criteria across our active primary care network.
Digital Engagement
Pre-screening questionnaires are sent to patients via SMS/email/letter on behalf of their trusted healthcare provider.
Nurse Screening
Our trained study nurses conduct follow-up calls to confirm eligibility, assess interest, and prepare patients for referral.
Eligible
Engaged, informed, protocol-ready patients delivered directly to your trial sites.
The uMed Difference
Smarter screening.
Stronger referrals.
Stronger referrals.
uMed identifies and refers highly qualified patients to clinical trial sites through a unique, multi-layered screening process. By combining EHR review, digital pre-screening, and nurse-led clinical assessment, we filter out ineligible patients early — before they ever reach the site.
As a result, sites receive fewer referrals, but of significantly higher quality. Patients referred by uMed are more likely to meet eligibility criteria and progress to randomisation, reducing unnecessary screening activity and workload for site teams.
Lowers site burden
Avoid excess screening
Reduce staff time
Improve timeline efficiency
The uMed Difference
From first outreach to first randomised - in weeks
By combining validated EMR-driven identification, automated outreach, and nurse-led screening, uMed Recruit delivers remarkably fast turnaround:
Days to first patient engagement
Weeks to first referral
Weeks to first randomisation
First nurse screening
15 Days
First referral
23 Days
First patient randomised
57 Days
The uMed Difference
A broad, expanding network — reaching patients beyond traditional sites.
Over 500 primary care practices engaged, giving access to millions of patients across UK & US primary care networks.
Designed to reach patients often excluded from traditional trials — improving representativeness, diversity, and inclusion.
Flexibility for sponsors: whether small site-based trials or large multi-site studies, uMed can scale recruitment efforts rapidly across the network.
Study service solutions
Comparison of umed & others (Placehold heading)
Patient Identification
Pre-referral screening
Ineligible patients filtered out
Quality of referrals
Likelihood of randomisation
Impact on sites
Impact on sponsors
uMed
EHR-driven identification grounded in real clinical data
Multi-layered: EHR review, digital e-screening, and nurse-led assessment
Majority removed before referral to site
Highly qualified, site-ready patients
Higher - patients closely matched to protocol
Reduced screening workload and staff burden
Faster recruitment, lower site costs, better trial efficiency
Other Recruitment Vendors
Broad outreach with limited clinical context
Minimal or single-step screening
Many screened out at site
Higher volume, lower qualification
Lower - more screen failures
Increased workload and inefficiency
Higher hidden costs and slower timelines
Compliance
Security-first recruitment that meets the highest regulatory standards.
At uMed we prioritise patient trust — ensuring privacy, transparency, and compliance every step of the way.
Fully ISO27001 and ISO9001 certified, Cyber Essentials Plus and NHS Digital Data & Security Toolkit certified.
HIPAA-compliant platform for cross-border trials.
Personal identifiable data (PII) is stored separately from health data — only encrypted link identifiers connect them.
Data use is strictly limited — only for approved studies with explicit patient consent. Any health data shared with researchers is always de-identified.
Patients are always in control: they can opt out at any time. No data is used for marketing or unrelated purposes.
Case Study
Real Studies. Real Results.
CMvibe
CMVibe Study is a Placebo-Controlled, Safety and Immunogenicity Study of the mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants Aged 9 to 15 Years.
178
Highly qualified referrals.
16,526
Patients Engaged
5
uMed-supported sites
95%
PDQ-39 completion
“uMed contributed to 38% of all screening activity in the UK! No small feat. We recognize that this is a very difficult study to enroll in, and we are grateful for all of the work that your team put in to help us try to meet our enrollment goals.”
Shane Walsh
